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Background: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with
acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large
observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study.
Methods: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the
outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients
with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure
were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on
day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≥ 0.60 during hyperoxemia).
Results: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%)
had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out
of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic
patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between
day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in
patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55–100mmHg)
patients (P = 0.47).
Conclusions: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained.
No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort.
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 Hyperoxemia and excess FIO2 use was prevalent in
patients with early ARDS. Hyperoxemia occurred in
30% of patients, while two thirds of these patients
received excess oxygen therapy.
 While a similar proportion of patients were
hyperoxemic on day 2 of ARDS, higher FIO2 use did
decrease. Consequently, most day 2 hyperoxemia
was seen in patients at lower FIO2, in whom gas
exchange was improving.
 In the majority of patients, both hyperoxemia and
excess oxygen use were transient, although sustained
hyperoxemia occurred in 12% of patients.
 Higher FIO2 use was independently associated with
the risk of hyperoxemia, illustrating the need for
close attention to oxygen use to reduce this risk.
 We found no relationship between the degree and
duration of hyperoxemia or of excessive oxygen use,
and outcome in early ARDS, in this patient cohort.
Background
Acute respiratory distress syndrome (ARDS) is a syn-
drome characterized by impaired gas exchange resulting
in low oxygen tensions in the blood (i.e., hypoxemia)
and tissues (i.e., hypoxia) [1]. Tissue hypoxia is harmful,
leading to cell death, organ failure, and increased mor-
tality in the critically ill [2]. While oxygen therapy can
reverse tissue hypoxia, little evidence exists regarding
the optimal use of oxygen in patients with ARDS. Critic-
ally ill patients frequently receive higher inspired oxygen
concentrations than necessary [3], perhaps due to con-
cerns regarding tissue hypoxia [4, 5].
Hyperoxemia and the resultant tissue hyperoxia may
worsen systemic organ injury in the critically ill. Arterial
hyperoxemia has been associated with increased mortality
in some older [6–8] but not more recent [9, 10] studies of
patients with acute brain injury. Hyperoxemia was associ-
ated with worse outcomes in cohort patients with acute is-
chemic stroke or subarachnoid/intracerebral hemorrhage
that required invasive mechanical ventilation [11]. Supple-
mental oxygen therapy worsened myocardial injury and
infarct size in patients post myocardial infarction [12]. In
patients resuscitated post cardiac arrest, hyperoxia has
been associated with harm in several [13–16] studies,
although the most recent study [17] did not confirm this.
Potential mechanisms of oxygen toxicity remain poorly
understood and may include systemic arterial vasoconstric-
tion [18, 19], and cytotoxic effects of reactive oxygen spe-
cies [20–22]. In randomized trials, “induced” hyperoxia
(using 100% oxygen) increased 28-day mortality in septic
shock patients [23], while critically ill patients randomized
to a target arterial oxygen tension (PaO2) of 70–100mmHg
had lower mortality compared to patients with a “conven-
tional” target of PaO2 up to 150mmHg [24] in a single-center study. While a recent large international multicenter
trial demonstrated no effect of conservative oxygen therapy
in a diverse cohort of critically ill patients [25], a subse-
quent sub-study raised the possibility of clinically import-
ant harm with conservative oxygen therapy in patients
with sepsis [26].
In ARDS, the relationship between oxygen use and
outcome is complex. The severely impaired gas exchange
means that high fraction of inspired oxygen (FIO2) use may
simply reflect a more severe alveolar-arterial oxygen gradi-
ent and hence be a marker of ARDS severity. In mild
ARDS, relatively modest levels of FIO2 may result in (mod-
erate) hyperoxemia and tissue hyperoxia. In addition, severe
degrees of systemic hyperoxemia (i.e., PaO2 > 300) associ-
ated with harm in other critically ill populations are not
possible in ARDS. However, even moderate systemic hyper-
oxemia that may be more commonly seen in ARDS could
be harmful [27]. Furthermore, the use of high FIO2 can
have direct toxic effects on the lung [28, 29], sensitize the
lung to subsequent injury, adversely affect the lung innate
immune response [30], and worsen ventilation-induced in-
jury [31–33]. These complexities highlight the need to dis-
tinguish between hyperoxemia and high FIO2 use. In
patients receiving high FIO2, it is important to determine
whether this was necessary to achieve normoxemia or if it
could have been avoided (i.e., excess oxygen use).
We wished to examine the impact of hyperoxemia and
of excess oxygen use in this secondary analysis of pa-
tients with ARDS in the LUNG SAFE patient cohort
[34]. Our primary objective was to determine the preva-
lence of early and sustained hyperoxemia and of excess
oxygen use in patients with hyperoxemia. Secondary ob-
jectives included identifying factors associated with
hyperoxemia and with excess oxygen use and examining
the relationship between hyperoxemia and excess oxygen
use and outcomes from ARDS.
Methods
Design, setting, and participants
This is a sub-study of the LUNG SAFE study, an inter-
national, multicenter, prospective cohort study of pa-
tients receiving invasive or noninvasive ventilation, and
the detailed methods and protocol have been published
elsewhere [34]. In brief, LUNG SAFE was an inter-
national, multicenter, prospective cohort study, with a 4-
week enrolment window in the winter season in both
hemispheres [34]. National coordinators and site investi-
gators obtained ethics committee approval and ensured
data integrity and validity.
Given the study focus on early hyperoxemia and ex-
cess oxygen use, we restricted the study population to
patients that fulfilled ARDS criteria within 48 h of ICU
admission, and who remained in the ICU for at least 2
days from ARDS onset. Patients transferred from other
Madotto et al. Critical Care          (2020) 24:125 Page 3 of 17ICUs after 2 days, patients that developed ARDS later in
their ICU stay, and patients that received early ECMO
were excluded (Fig. 1). Additional methodological details
are available in Additional file 1.
Data collection and analysis
All data were recorded for each patient at the same time
each day within participating ICUs, normally as close as
possible to 10 a.m. each day. Data on ventilatory settings
were recorded simultaneously with arterial blood gas
analysis. The following definitions were applied on day 1
and on day 2 of ARDS: hypoxemia (PaO2 < 55mmHg),
normoxemia (PaO2 55–100 mmHg), and hyperoxemia
(PaO2 > 100 mmHg). Excess oxygen use was defined as
the use of FIO2 ≥ 0.6 in patients with hyperoxemia
(PaO2 > 100 mmHg). Patients with hyperoxemia on days
1 and 2 of ARDS were considered to have sustained
hyperoxemia. Analogously, we also defined patients with
sustained hypoxemia and sustained normoxemia.
The duration of invasive mechanical ventilation (MV)
was calculated as the number of days between the date
of intubation and the date of extubation in ICU (orFig. 1 Flow chart describing criteria used to select and to classify the ARDSdeath, if the patient died under invasive MV). Similarly,
invasive ventilator-free days were calculated as the num-
ber of days from weaning from invasive MV to day 28,
and for patients who died before weaning, we considered
to have a ventilator-free-day value of 0. Patient survival
was evaluated at hospital discharge, or at day 90, which-
ever occurred first. Our other data definitions have been
previously reported [34–37].
Statistical analyses
Descriptive statistics included proportions for categorical
and mean (standard deviation) or median (interquartile
range) for continuous variables. No assumptions were
made for missing data. To assess differences among
three groups (systemic hypoxemia, normoxemia, and
hyperoxemia), we performed chi-squared test (or Fisher
exact test) for discrete variables and analysis of variance
(ANOVA) (or Kruskal-Wallis test) for continuous vari-
ables. Bonferroni correction was applied to determine
significance in the setting of multiple comparisons.
Chi-square test (or Fisher exact test), Student’s t test
(or Wilcoxon Mann Whitney test) were used to assessstudy population
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and sustained normoxemia) in discrete and continuous
distributions of parameters, respectively.
Locally estimated scatterplot smoothing (LOESS)
method was used to inspect the relationship between
mortality and PaO2 and FIO2 measured on day 1 and on
day 2 of ARDS.
Multivariable logistic regression models were used to
evaluate factors associated with the presence of either
hyperoxemia or excess of oxygen use, and with mortality.
In each regression model, the independent predictors
(demographic characteristics and clinical parameters mea-
sured at the first day of ARDS) were identified through a
stepwise regression approach. This approach combines
forward and backward selection methods in an iterative
procedure (with a significance level of 0.05 both for entry
and retention) to select predictors in the final multivari-
able model. Results were reported as odds ratio (OR) with
95% confidence interval (CI).
Propensity score matching method was applied to
evaluate the possible impact of sustained hyperoxemia
on main outcomes (mortality, ventilation-free days, and
duration of MV) in patients with mild-moderate ARDS.Fig. 2 Arterial oxygen tensions and use of oxygen in patients on days 1 and
wide range of PaO2. b Density distributions of PaO2 on days 1 (red line) and d
ARDS. d Histogram of FIO2 and PaO2 on day 2 of ARDS. Note: in c and d, eac
hypoxemia (light gray), and unknown (white) componentPatients with severe ARDS were excluded as there were
no such patients in the sustained hyperoxemia group. In
detail, patients with sustained hyperoxemia and sus-
tained normoxemia were matched (1:1 match without
replacement), using a caliper of 0.2 standard deviation of
the logit of the propensity score, and the balance be-
tween the matched groups was assessed by the standard-
ized differences of each independent variable used in the
propensity score estimation. Statistical significance of
the difference in continuous variables, as ventilation-free
days and duration of MV, was evaluated with Wilcoxon
signed-rank test, while for difference in proportions of
deaths, we applied McNemar’s test. Survival probability
in these matched groups was estimated using the
Kaplan-Meier approach and assuming that patients dis-
charged alive from hospital before 90 days were alive on
day 90. Statistical difference between survival curves was
assessed through Kein and Moeschberger test. The same
approach was used to assess the possible impact of ex-
cess use of oxygen on main outcomes.
All p values were two-sided, with p values < 0.05 con-
sidered as statistically significant. Statistical analyses
were performed with R, version 3.5.2. (R Project for2 of ARDS. a The distribution of PaO2 on day 1 of ARDS, demonstrating a
ay 2 (blue line) of ARDS. c Histogram of FIO2 and PaO2 on day 1 of
h bar is segmented into hyperoxemia (black), normoxemia (dark gray),
Table 1 Characteristics of study population (n = 2005), stratified by arterial oxygenation on day 1
Parameter Hypoxemia








N (%) 131 (6.53) 1267 (63.19) 607 (30.27)
Male, n (%) 73 (55.73) 796 (62.83) 359 (59.14) 0.1259
Age (years), mean ± SD 59.20 ± 16.86 62.21 ± 16.74 61.88 ± 16.82 0.1264
BMI (kg/m2), mean ± SD 27.23 ± 6.82 27.66 ± 8.26 26.90 ± 6.84 0.5646
ARDS risk factors, n (%)
None 9 (6.87) 103 (8.13) 52 (8.57) 0.8088
Only non-pulmonary 15 (11.45) 229 (18.07) 106 (17.46) 0.1641
Only pulmonary 92 (70.23) 769 (60.62) 357 (58.81) 0.0525
Both 15 (11.45) 167 (13.18) 92 (15.16) 0.3789
Illness severity at ARDS onset
PaO2 (mmHg), mean ± SD 47.1 ± 6.2 76.8 ± 11.9* 137.8 ± 41.0*
† < 0.0001
PaO2/FIO2 (mmHg), mean ± SD 75.12 ± 38.97 140.49 ± 56.70* 205.90 ± 54.88*
† < 0.0001
SpO2 (%), median (q1–q3) 88 (82–94) 95 (92–97)* 98 (97–99)*
† < 0.0001
ARDS severity, n (%) < 0.0001
Mild 4 (3.05) 205 (16.18)* 330 (54.37)*† < 0.0001
Moderate 22 (16.79) 683 (53.91)* 273 (33.98)*† < 0.0001
Severe 105 (80.15) 379 (29.91)* 4 (0.66)*† < 0.0001
PaCO2 (mmHg), mean ± SD 54.3 ± 25.0 46.3 ± 15.3* 44.8 ± 14.6* 0.0031
pH, mean ± SD 7.31 ± 0.15 7.33 ± 0.12 7.32 ± 0.13 0.7446
Bicarbonate (mmol/L), mean ± SD 26.3 ± 10.9 23.3 ± 6.5 22.3 ± 6.3*† < 0.0001
Base excess (mEq/L), mean ± SD 0.5 ± 10.8 −2.0 ± 6.8 −3.1 ± 6.8*† 0.0001
Non-respiratory SOFA score adjusted, mean ± SD 6.14 ± 4.15 6.08 ± 3.94 6.28 ± 4.00 0.6246
SOFA score adjusted, mean ± SD 10.25 ± 4.20 9.51 ± 3.98 8.87 ± 3.93*† 0.0005
Respiration 3.79 ± 0.46 3.15 ± 0.66 2.45 ± 0.50 < 0.0001
Central nervous system 1.68 ± 1.72 1.74 ± 1.66 1.92 ± 1.69 0.1161
Cardiovascular 1.77 ± 1.74 2.03 ± 1.76 1.93 ± 1.74 0.1760
Liver 0.65 ± 0.98 0.54 ± 0.96 0.51 ± 0.92 0.2855
Coagulation 1.20 ± 1.45 0.95 ± 1.31 0.98 ± 1.34 0.1751
Renal 0.69 ± 1.04 1.77 ± 1.10 0.88 ± 1.22 0.3333
Pressor support infusion rates
Dopamine (μg/kg/min), mean ± SD 8.19 ± 6.94 8.58 ± 5.02 7.73 ± 5.98 0.4151
Dobutamine (μg/kg/min), mean ± SD 5.52 ± 3.74 5.72 ± 4.05 6.75 ± 3.53 0.3565
Noradrenaline (μg/kg/min), mean ± SD 0.50 ± 0.67 0.45 ± 0.75 0.54 ± 1.48 0.6701
Adrenaline (μg/kg/min), mean ± SD 1.10 ± 2.03 0.48 ± 0.69 0.43 ± 0.55 0.8434
Management factors at ARDS onset
Invasive mechanical ventilation, n (%) 102 (77.86) 1000 (78.93) 506 (83.36) 0.0619
Control mode of ventilation, mean ± SD 70 (54.69) 693 (55.89) 386 (64.23)† 0.0021
FIO2, median (q1–q3) 0.80 (0.50–1.00) 0.60 (0.41–0.80)* 0.65 (0.50–1.00)
† < 0.0001
FIO2 ≥ 0.6, n (%) 90 (68.70) 670 (52.88)* 400 (65.90)
† < 0.0001
FIO2 ≥ 0.6 at 2nd day, n (%)
‡ 64 (73.56) 372 (57.94)* 167 (43.60)*† < 0.0001
Tidal volume (ml/kg), mean ± SD 7.9 ± 2.2 7.8 ± 2.0 7.9 ± 2.0 0.2256
PEEP (cmH2O), mean ± SD 8.7 ± 3.33 8.1 ± 3.2 7.9 ± 3.1* 0.0174
PIP (cmH2O), mean ± SD 25.7 ± 8.90 25.3 ± 8.5 25.6 ± 8.7 0.6295
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Table 1 Characteristics of study population (n = 2005), stratified by arterial oxygenation on day 1 (Continued)
Parameter Hypoxemia








Dynamic compliance (ml/cmH2O), mean ± SD 39.0 ± 38.4 36.9 ± 37.8 35.6 ± 38.9 0.7759
Total respiratory rate (breaths/min), mean ± SD 23.2 ± 7.1 21.9 ± 6.9 21.1 ± 7.0 0.0003
Standardized minute ventilation (L/min), mean ± SD 14.4 ± 7.8 11.4 ± 5.3* 10.8 ± 5.0*† < 0.0001
Patients in whom plateau pressure measured, n (%)° 24 (18.32) 304 (23.99) 186 (30.64) 0.0012
Plateau pressure (cmH2O), mean ± SD 24.3 ± 9.0 23.4 ± 6.1 23.0 ± 5.6 0.7512
Driving pressure (cmH2O), mean ± SD 16.0 ± 8.2 14.6 ± 5.4 15.0 ± 5.2 0.4941
Clinical outcomes
Hospital mortality (90 days), n (%) 47 (35.88) 486 (38.54) 227 (37.52) 0.7934
Ventilation free days (days), median (q1–q3)
All 10.0 (0.0–22.0) 12.0 (0.0–23.0) 16.0 (0.0–24.0)† 0.0303
Survivors at ICU discharge 20.0 (14.0–24.0) 21.0 (15.0–25.0) 23.0 (18.0–26.0)*† 0.0002
Duration mechanical ventilation (days), median (q1–q3)
All 7.0 (4.0–13.0) 8.0 (4.0–15.0) 7.0 (3.0–13.0)† 0.0074
Survivors at ICU discharge 9.0 (5.0–15.0) 8.0 (4.0–14.0) 6.0 (3.0–11.0)*† 0.0002
Abbreviations: ARDS acute respiratory distress syndrome, BMI body mass index, COPD chronic obstructive pulmonary disease, FIO2 fraction of inspired oxygen, PaO2
arterial oxygen partial pressure, PaCO2 arterial carbon dioxide partial pressure, PEEP positive end-expiratory pressure, PIP peak inspiratory pressure, q1 first quartile,
q3 third quartile, SOFA sepsis-related organ failure assessment, SD standard deviation, SpO2 peripheral oxygen saturation
°Plateau pressure and driving pressure values are limited to patients in whom this value was reported and in whom either an assist control mode was used or in
whom a mode permitting spontaneous ventilation was used and where the set and total respiratory rates were equal. Patients receiving HFOV or ECMO were
also excluded
‡Percentage was calculated on patients with FIO2 available during the second day and with FIO2 ≥ 0.60 at day 1
*p value < 0.05 (Bonferroni’s correction), comparison with “Hypoxemia” group
†p value < 0.05 (Bonferroni’s correction), comparison with “Normoxemia” group
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SAS software, version 9.4 (SAS Institute, Cary, NC,
USA).
Results
Of 4499 patients that developed AHRF in the LUNG
SAFE cohort, 2127 of these developed ARDS within 2
days of ICU admission, of whom 2052 remained in ICU
for at least 2 days from ARDS onset. The study popula-
tion consists of 2005 of these patients that did not re-
ceive ECMO (Fig. 1).
Systemic oxygen tensions
In the study population, 607 subjects (30%) were hyper-
oxemic, while 6.5% of patients remained hypoxemic, on
day 1 of ARDS (Fig. 2a, Table 1, eTable 1). Density dis-
tributions of arterial oxygen tension on days 1 and 2 of
ARDS (Fig. 2b) reveal similar PaO2 profiles for days 1
and 2. In the hyperoxemic population at day 1, 59% had
a transient hyperoxemia, while in 250 (41%) patients, the
condition was sustained, with PaO2 > 100 mmHg on
both the first and second day of ARDS (Fig. 1; eTable 2).
All eTables are included in Additional file 1.
A multivariable analysis of factors independently asso-
ciated with day 1 hyperoxemia identified higher FIO2
use, lower PEEP, lower respiratory rate, a lower sepsis-related organ failure assessment (SOFA) cardiovascular
score, and comorbidities such as neoplasm and/or im-
munosuppression and heart failure (Table 2).
Use of oxygen
FIO2 use varied widely across the spectrum of PaO2 on
day 1 of ARDS (Fig. 2c). In patients that received a FIO2
greater than 0.9 (459 patients), 11% had systemic hypox-
emia, while 38% had hyperoxemia (Fig. 2c). Median
PaO2 was similar across deciles of FIO2 (Fig. 3a). On day
2 of ARDS, the proportions of patients receiving higher
FIO2 decreased, although around one third of patients
were hyperoxemic at each decile of FIO2 (Figs. 2d and 3b,
c). In contrast, 40% (57/131) of patients with hypoxemia
on day 1 received a FIO2 of 0.5 or less. Median FIO2
decreased between day 1 and day 2 in patients with hyper-
oxemia, normoxemia, and hypoxemia (Fig. 3b), although
median PaO2 remained similar across deciles of FIO2 on
day 2 (Fig. 3c).
Excess oxygen use was seen in 400 patients, compris-
ing 66% of all patients with hyperoxemia, on day 1 of
ARDS (Table 1). In 315 patients (79%), excess oxygen
use was transient, while in 85 (21%) patients, excess
oxygen use was also seen on day 2 of ARDS. In multi-
variable analysis, factors independently associated with
excess oxygen use included lower PaO2/FIO2 ratio,
Table 2 Factors associated with day 1 hyperoxemia (PaO2 > 100 mmHg) and with excess oxygen use (FIO2 ≥ 0.6 in patients with
PaO2 > 100 mmHg) in the study population
Parameter Odds ratio (95% confidence interval) p value
Outcome—hyperoxemia at day 1 (model* on 1855 patients)
FIO2 (0.1 unit) 1.168 (1.115; 1.224) < .0001
Bicarbonate (mmol/L) 0.967 (0.951; 0.984) < .0001
Total respiratory rate (breath/min) 0.971 (0.956; 0.986) 0.0002
PEEP (cmH2O) 0.944 (0.910; 0.979) 0.0017
Active/hematologic neoplasm or immunosuppression (ref. no.) 1.414 (1.111; 1.801) 0.0050
SOFA score – Cardiovascular 0.925 (0.870; 0.984) 0.0139
Heart failure (ref. no.) 1.482 (1.080; 2.033) 0.0148
Outcome—excess oxygen use at day 1 (model° on 1694 patients)
PaO2/FIO2 (mmHg) 0.978 (0.976; 0.980) < .0001
PEEP (cmH2O) 1.144 (1.091; 1.199) < .0001
PIP (cmH2O) 1.029 (1.014; 1.045) 0.0002
Bicarbonate (mmol/L) 0.971 (0.954; 0.989) 0.0013
Age (years) 0.988 (0.981; 0.996) 0.0023
BMI (kg/m2) 0.980 (0.965; 0.995) 0.0111
Tidal volume (ml/kg IBW) 1.081 (1.017; 1.149) 0.0122
Abbreviations: BMI body mass index, FIO2 fraction of inspired oxygen, PEEP positive end-expiratory pressure, PIP peak inspiratory pressure, SOFA sepsis-related
organ failure, PaO2 arterial oxygen partial pressure, IBW ideal body weight
*Multivariable logistic model with presence of hyperoxemia (PaO2 > 100 mmHg) as dependent dichotomous variable and the predictors were identified by
stepwise approach. One hundred and fifty patients were excluded due to missing values for the response or explanatory variables. List of possible predictors in
stepwise approach: age, sex, body mass index, comorbidities (presence of heart failure, diabetes mellitus chronic renal failure, chronic obstructive pulmonary
disease or home ventilation, active neoplasm of hematologic neoplasm or immunosuppression), ARDS risk factors (none, only non-pulmonary, only pulmonary,
both types), bicarbonates concentration, management factors (presence of invasive mechanical ventilation, tidal volume, PEEP, PIP, total respiratory rate, minute
ventilation), and FIO2 and SOFA components (CNS, cardiovascular, renal, liver, coagulation score)
°Multivariable logistic model with excess of oxygen use (FIO2 ≥ 0.6 and PaO2 > 100mmHg) as dependent dichotomous variable and predictors identified by
stepwise approach. Three hundred and eleven observations were deleted due to missing values for the response or explanatory variables
List of possible predictors in stepwise approach: age, sex, body mass index, comorbidities (presence of heart failure, diabetes mellitus chronic renal failure, chronic
obstructive pulmonary disease or home ventilation, active neoplasm of hematologic neoplasm or immunosuppression), ARDS risk factors (none, only non-
pulmonary, only pulmonary, both types), bicarbonates concentration, management factors (presence of invasive mechanical ventilation, tidal volume, PEEP, PIP,
total respiratory rate, minute ventilation), and PaO2/FIO2 ratio and non-respiratory SOFA components (CNS, cardiovascular, renal, liver, coagulation score)
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failure (Table 2).
Hyperoxemia, excess oxygen use, and outcome
On day 1, LOESS demonstrated the relationship between
unadjusted mortality risk and PaO2 was relatively flat
over the range of PaO2 (Fig. 4a). On day 2, the unadjusted
risk of hospital mortality increased in patients with systemic
hypoxemia (Fig. 4b). LOESS in non-hypoxemic patients
demonstrated that unadjusted mortality risk increased with
increasing FIO2 on both days 1 and 2 (Fig. 4c, d).
Multivariate analyses found no independent associ-
ation between day 1 systemic oxygen tension or inspired
oxygen concentration and outcome, in either the full
study population or in the subset of patients with hyper-
oxemia (Table 3).
In a propensity-matched analysis (n = 448), no out-
come differences were found in patients with sustained
hyperoxemia compared to matched sustained normoxe-
mia patients (Fig. 5a; eTable 3). Similarly, mortality in
patients with hyperoxemia and excess oxygen use (42%)was not different to that in patients with normoxemia
(39%, P = 0.47) in a propensity-matched sample (n = 666)
(Fig. 5b; eTable 4).
Discussion
Our findings demonstrate that hyperoxemia and excess
FIO2 use was prevalent in patients with early ARDS in
patients enrolled in the LUNG SAFE cohort. Hyperoxe-
mia occurred in 30% of patients, while two thirds of
these patients received excess oxygen therapy. While a
similar proportion of patients was hyperoxemic on day 2
of ARDS, higher FIO2 use did decrease. Consequently,
most day 2 hyperoxemia was seen in patients at lower
FIO2, in whom gas exchange was improving. In the
majority of patients, both hyperoxemia and excess
oxygen use were transient, although sustained hyperoxe-
mia occurred in 12% of patients. Higher FIO2 use was
independently associated with the risk of hyperoxemia,
illustrating the need for close attention to oxygen use to
reduce this risk. We found no relationship between the
degree and duration of hyperoxemia or of excessive
Fig. 3 Use of inspired oxygen in patients on days 1 and 2 of ARDS. a A box plot of PaO2 at each decile of FIO2 uses on day 1 of ARDS. b A box
plot of FIO2 used on day 1 and 2 of ARDS in the study population classified by PaO2 on day 2 (hypoxemia, normoxemia, hyperoxemia, and
unknown). c A box plot of PaO2 at each decile of FIO2 used on day 2 of ARDS
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cohort.
Oxygen use in ARDS
The optimal use of oxygen in patients with ARDS re-
mains unclear. While guidelines recommend the use of
supplemental oxygen during acute hypoxemia [38], spe-
cific therapeutic goals in terms of PaO2 or SpO2 are
lacking. The ARDS Network targeted a PaO2 of 55–80
mmHg in the ARMA trial of patients with ARDS [39].
The British Thoracic Society suggested a target SpO2 of
94–98% in acutely ill patients who are not at risk of
hypercapnic respiratory failure (only Grade D recom-
mendation) [40, 41].
Tissue hypoxia directly causes cellular death, leading
to organ failure and increased mortality in ICU patients.
In contrast, high oxygen concentrations may be directly
toxic to the lung via mechanisms that remain poorly
characterized but may include alveolar-capillary “leak”
and fibrogenesis [42, 43], arterial vasoconstriction
[18, 19], and the production of reactive oxygen spe-
cies with consequent proinflammatory and cytotoxic
effects [20–22]. Consequently, clinicians are faced with
the task of titrating the amount of oxygen delivered toavoid both hypoxemia and hyperoxemia. Prior studies
show that clinicians appear to use higher FIO2 than is
necessary in the critically ill [3]. While the reasons are un-
clear, potential explanations include concerns over the
need to avoid tissue hypoxia, [4, 5] a desire to provide a
“buffer” should a clinical deterioration occur, or because
the consequences of hyperoxia are considered less severe
than hypoxia.Hyperoxemia in ARDS
In this study, hyperoxemia was seen on day 1 in a third
of ARDS patients enrolled in the LUNG SAFE study.
The fact that hyperoxemia was more prevalent than hyp-
oxemia in patients immediately following the onset of
ARDS, might seem surprising given that ARDS is a syn-
drome defined by impaired gas exchange but presumably
reflects the effectiveness of ventilatory support and oxy-
gen therapy. Of interest, hyperoxemia was associated
with lower SOFA cardiovascular scores, suggesting that
clinicians were not permitting hyperoxemia as a “buffer”
in patients with shock. In this patient cohort, hyperoxe-
mia was relatively transient in the majority of patients in
early ARDS.
Fig. 4 Relationship between oxygen and outcome in patients with ARDS. a A locally estimated scatterplot smoothing (LOESS) of the relationship
between PaO2 on day 1 of ARDS and mortality risk. b A LOESS of the relationship between PaO2 use on day 2 of ARDS and mortality risk. c A
LOESS of the relationship between FIO2 use on day 1 in non-hypoxemic patients with ARDS and mortality risk. d A LOESS of the relationship
between FIO2 use on day 2 in non-hypoxemic patients with ARDS and mortality risk. Note: LOESS uses a bandwidth 2/3 and 1 degree of
polynomial regression
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this cohort. Interestingly, day 2 median FIO2 was the
same in patients with sustained hyperoxemia and nor-
moxemia, while P/F ratio was substantially higher in the
hyperoxemic patients. These findings suggest that sus-
tained hyperoxemia in these patients is a function of
rapidly improving gas exchange rather than excess oxy-
gen use. Sustained hyperoxemia did not have a demon-
strable impact on patient mortality. In the matched
propensity score analysis, outcomes in patients with sus-
tained hyperoxemia were comparable to that seen in
normoxemic patients.
These findings contrast with prior findings regarding
hyperoxemia in other critically ill cohorts. However, an
important difference between these studies and the
current study relates to the severity of hyperoxemia. De
Jonge and colleagues reported an association between
early hyperoxemia and outcome in patients with acute
respiratory failure in the Netherlands [44]. However, this
association was only seen in patients with relatively se-
vere hyperoxemia (PaO2 > 123 mmHg; uncommon in
our cohort) and only on day 1 of ICU admission, whilethere was no adverse association between hyperoxia over
the entire ICU stay and patient outcome. The potential
for harm from hyperoxia in the critically ill appears to
be enhanced with greater severity and “dose” of hyperox-
emia [45]. In fact, in critically ill patient groups where
lung function was relatively preserved, such as patients
post cardiac arrest, harm was mainly associated with
systemic oxygen tensions over 300 mmHg [13]. Greater
degrees of hyperoxemia were likely in both the study by
Girardis et al. [24] and in the HYPERS2S trial [23] of
“induced” systemic hyperoxemia in patients with sepsis.
Our study was focused solely on patients with ARDS,
where due to their impaired gas exchange, they cannot
attain this severity of systemic hyperoxia.
Oxygen use in ARDS
High inspired oxygen use was frequent in patients on
day 1 of ARDS, with two thirds of patients with systemic
hyperoxia receiving at least 60% oxygen in day 1—which
we termed “excess oxygen use” on the basis that these
patients could safely have had their FIO2 reduced while
maintaining normoxemia. Of importance, high FIO2 use
Table 3 Factors associated with hospital mortality in study population (n = 2005) and in patients with hyperoxemia at day 1 (n = 607)
Factor Odds ratio (95% confidence interval) p value
Study population (n = 2005)—model on 1360 patients
Age (year) 1.022 (1.015; 1.030) <.0001
BMI (kg/m2) 0.978 (0.962; 0.995) 0.0098
SOFA score—cardiovascular 1.182 (1.096; 1.275) <.0001
SOFA score—respiratory 1.405 (1.182; 1.669) 0.0001
SOFA score—renal 1.209 (1.087; 1.344) 0.0005
SOFA score—central nervous system 1.147 (1.061; 1.240) 0.0006
Active/hematologic neoplasm or immunosuppression (ref. no.) 2.248 (1.697; 2.978) <.0001
Chronic liver failure (ref. no.) 4.315 (2.184; 8.523) <.0001
PIP (cmH2O) 1.030 (1.013; 1.046) 0.0003
Invasive mechanical ventilation (ref. no.) 0.497 (0.339; 0.729) 0.0004
Bicarbonate (mmol/L) 0.979 (0.960; 0.997) 0.0240
Patients with PaO2 > 100mmHg (n = 607)—model on 530 patients
Age (year) 1.031 (1.018; 1.044) <.0001
SOFA score —renal 1.362 (1.152; 1.610) 0.0003
SOFA score—cardiovascular 1.205 (1.073; 1.352) 0.0016
Active/hematologic neoplasm or immunosuppression (ref. no) 1.828 (1.186; 2.819) 0.0063
Chronic liver failure (ref. no.) 4.091 (1.256; 13.328) 0.0194
Total respiratory rate (breath/min) 1.043 (1.015; 1.072) 0.0027
Bicarbonate (mmol/L) 0.958 (0.924; 0.994) 0.0210
Abbreviations: BMI body mass index, PIP peak inspiratory pressure, SOFA sepsis-related organ failure assessment
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higher inspired oxygen concentration use on day 2.
Nevertheless, at each decile of FIO2, approximately one
third of patients were hyperoxemic, suggesting the po-
tential existed to further reduce oxygen use. Of interest,
there was an association between excess oxygen use and
the use of higher tidal volumes.
Our unadjusted analyses suggested an association be-
tween higher FIO2 and poorer outcome. However, in
multivariate analyses, which accounted for lung injury
severity, we found no independent association between
high FIO2 use and patient outcome. Propensity-matched
analyses in patients excess FIO2 confirmed no difference
in mortality compared to normoxemic patients.
Our findings do not support prior concerns [24] raised
regarding the use of higher FIO2 in patients with ARDS
that are not hypoxemic. This finding also contrasts with
the analysis of patients in the ARDS Network trials
that found that the cumulative duration of “above tar-
get” oxygen exposure (FIO2 above 0.5 in ARDS pa-
tients while PaO2 was > 80 mmHg) was associated
with mortality [27]. While the reasons for the diver-
gent findings are unclear, potential explanations in-
clude the fact that our analysis concentrated on early
ARDS, the fact that high FIO2 use was transient in
most patients in our cohort, and the fact that thisanalysis may have been better adjusted for the impact
of lung injury severity.Limitations
This study has several limitations. The non-linearity of
P/F ratio at different FIO2 [46] makes it difficult to pre-
dict the effect of FIO2 on PaO2/FIO2, especially when
matching patients with mild ARDS. While we have ad-
justed our analyses to account for known measured con-
founders, the possibility remains that some of our
findings may arise from unmeasured or residual con-
founding. Moreover, we cannot make causal inferences
for any associations seen, given the observational nature
of our study. Our dataset comprises daily arterial blood
gas and FIO2 data, taken at a standardized time each
morning. It is possible that these data do not properly
reflect the spectrum of FIO2 use and PaO2 data over the
course of that day. Given this, in the hyperoxemia ana-
lyses, we focused on patients that were hyperoxemic on
both days 1 and 2 of ARDS. There are no single ac-
cepted definitions for hyperoxemia, hypoxemia, or ex-
cess oxygen use, so our definitions are of necessity
arbitrary, and other definitions have been used in other
analyses. This could partly explain any divergence in
findings across these studies. Lastly, our assumption that
Fig. 5 Kaplan-Meier curves for hospital survival in matched samples. a Survival probability in matched sample (n = 448) of patients with sustained
normoxemia and with sustained hyperoxemia. b Survival probability in matched sample (n = 646) of patients with normoxemia and with excess
oxygen use at day 1. Notes: (1) Normoxemia is defined as 55mmHg≤ PaO2≤ 100mmHg on day 1 of ARDS, sustained normoxemia defined as
normoxemia on day 1 and 2 of ARDS, sustained hyperoxemia defined as PaO2 > 100mmHg on day 1 and 2 of ARDS, and excess oxygen use
defined as PaO2 > 100mmHg and FIO2 ≥ 0.60 on day 1 of ARDS. (2) Mortality is defined as mortality at hospital discharge or at 90 days,
whichever event occurred first. We assumed that patients discharged alive from the hospital before 90 days were alive on day 90. (3) The number
of patients at risk reported at the bottom of the figure is referred to as the end of the corresponding day
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further limitation.
Conclusions
Our findings demonstrate that hyperoxemia and high
fractional inspired oxygen use is prevalent in patients
with early ARDS in patients enrolled in the LUNG SAFE
cohort. Higher FIO2 use decreased from day 1 to day 2
of ARDS, with most day 2 hyperoxemia seen in patients
at lower FIO2, in whom gas exchange was improving.
Reassuringly, we found no relationship between hyper-
oxemia or excessive oxygen use and patient outcome in
this cohort.
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